TrialAnnals of hematology2023

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Steffen Koschmieder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.